{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:45:51Z","timestamp":1771296351654,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T00:00:00Z","timestamp":1417651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Laryngoscope"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:sec><jats:title>Objectives\/Hypothesis<\/jats:title><jats:p>Auralgan (benzocaine and antipyrine) is an over\u2010the\u2010counter otic drug commonly used for otalgia. Nevertheless, there is limited evidence about the effects of the drug on hearing function and cochlear morphology in the presence of a tympanic membrane perforation. The aim of the present study was to assess the cytotoxicity of Auralgan using cultured auditory cells (HEI\u2010OC1) and to examine its effects on hearing function and cochlear morphology after intratympanic administration in a chinchilla model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design<\/jats:title><jats:p>Animal experiment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cell viability and DNA labeling assays were conducted to investigate the cytotoxic effect of the drug on cultured auditory cells (HEI\u2010OC1). To examine the possible drug ototoxic effect in vivo, chinchillas received intratympanic injection of Auralgan in one ear, whereas the contralateral control ear received saline. Outcome measures included auditory brainstem response and postmortem cochlear morphology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A dose\u2010dependent toxic effect of Auralgan was noted on cultured cells. Animal experiments showed an inflammatory reaction in the experimental ears and facial paralysis in 80% of the animals on the side receiving transtympanic injection of Auralgan (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05). Auditory brainstem response testing demonstrated a 30\u2010 to 50\u2010dB hearing threshold shift across all frequencies tested (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05). Control ears showed no inflammation or significant threshold shift. Microscopy showed damage to the hair cells and stria vascularis with bleeding in the perilymphatic space in the experimental ears and damage to the hair cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Auralgan was cytotoxic to cultured auditory cells. It promoted an inflammatory reaction and seemed to be ototoxic when given via transtympanic injection in an animal model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Level of Evidence<\/jats:title><jats:p>NA <jats:italic>Laryngoscope<\/jats:italic>, 125:1444\u20131448, 2015<\/jats:p><\/jats:sec>","DOI":"10.1002\/lary.25080","type":"journal-article","created":{"date-parts":[[2014,12,6]],"date-time":"2014-12-06T14:49:38Z","timestamp":1417877378000},"page":"1444-1448","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of ototoxicity of intratympanic administration of <scp>A<\/scp>uralgan in a chinchilla animal model"],"prefix":"10.1002","volume":"125","author":[{"given":"Mario A.","family":"Mujica\u2010Mota","sequence":"first","affiliation":[{"name":"McGill Auditory Sciences Laboratory McGill University Montreal Quebec Canada"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery The Montreal Children's Hospital Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aren","family":"Bezdjian","sequence":"additional","affiliation":[{"name":"McGill Auditory Sciences Laboratory McGill University Montreal Quebec Canada"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery The Montreal Children's Hospital Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pezhman","family":"Salehi","sequence":"additional","affiliation":[{"name":"McGill Auditory Sciences Laboratory McGill University Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonah","family":"Schermbrucker","sequence":"additional","affiliation":[{"name":"McGill Auditory Sciences Laboratory McGill University Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam J.","family":"Daniel","sequence":"additional","affiliation":[{"name":"McGill Auditory Sciences Laboratory McGill University Montreal Quebec Canada"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery The Montreal Children's Hospital Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,12,4]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"721","article-title":"Characteristics of earache among children with acute otitis media","volume":"139","author":"Hayden GF","year":"1985","journal-title":"Am J Dis Child"},{"issue":"1","key":"e_1_2_7_3_1","first-page":"CD000219","article-title":"Antibiotics for acute otitis media in children","author":"Glasziou PP","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1997.02170440037006"},{"key":"e_1_2_7_5_1","unstructured":"Auralgan website.Available at:http:\/\/auralgan.ca\/. Update 2011. Accessed December 24 2013."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268813002744"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2013.3924"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedhc.2005.07.008"},{"key":"e_1_2_7_9_1","unstructured":"Antipyrine and benzocaine ear drops.Available at:http:\/\/en.wikipedia.org\/wiki\/Antipyrine_and_benzocaine_ear_drops. Accessed December 24 2013."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.1999.0619"},{"key":"e_1_2_7_11_1","volume-title":"Pharmacotherapeutics for Advanced Practice. A Practical Approach","author":"Zimmerman L","year":"2011"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1520\/JFS2005125"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2012.05.022"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020623"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2003.12.008"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLG.0b013e318148b275"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1121\/1.1912166"},{"key":"e_1_2_7_18_1","first-page":"CD008806","article-title":"Osmotic therapies added to antibiotics for acute bacterial meningitis","volume":"3","author":"Wall EC","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["The Laryngoscope"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flary.25080","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lary.25080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T17:35:54Z","timestamp":1696354554000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/lary.25080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,4]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1002\/lary.25080"],"URL":"https:\/\/doi.org\/10.1002\/lary.25080","archive":["Portico"],"relation":{},"ISSN":["0023-852X","1531-4995"],"issn-type":[{"value":"0023-852X","type":"print"},{"value":"1531-4995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,4]]}}}